Benznidazole is an antiparasitic medication primarily used to treat Chagas disease, caused by the Trypanosoma cruzi parasite. Its clinical significance lies in its ability to reduce morbidity and mortality associated with chronic Chagas disease, particularly in young patients, by targeting the parasite during the acute phase. A key association is its potential side effects, including allergic reactions and peripheral neuropathy, which necessitate careful monitoring during treatment.